CAPE inhibits mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) expression, reducing cell proliferation, invasion, and tumor growth through modulation of the p53 and NF-κB signaling pathways. This evidence concerns the gene MALT1 and neoplasm.